Abstract
BRL 36650 [sodium 6 beta-(D-2-[(4-ethyl-2, 3-dioxopiperazin-1-yl)carbonylamino]-2-(3,4-dihydroxyphenyl) acetamido)-6 alpha-formamido-penicillinate] is a new semisynthetic penicillin. It was tested in vitro for activity against 884 organisms cultured from blood specimens of cancer patients. BRL 36650 had broad-spectrum activity against the gram-negative bacilli tested but had no gram-positive activity. The MIC against 90% of the Pseudomonas aeruginosa isolates was 3.12 micrograms/ml. The activity of BRL 36650 was superior to that of piperacillin, comparable or slightly inferior to that of aztreonam and ceftazidime, and lower than that of imipenem and amifloxacin. BRL 36650 should prove useful for the management of gram-negative bacillary infections, including those caused by P. aeruginosa.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Basker M. J., Edmondson R. A., Knott S. J., Ponsford R. J., Slocombe B., White S. J. In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillin. Antimicrob Agents Chemother. 1984 Nov;26(5):734–740. doi: 10.1128/aac.26.5.734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodey G. P. Antibiotics in patients with neutropenia. Arch Intern Med. 1984 Sep;144(9):1845–1851. [PubMed] [Google Scholar]
- Bodey G. P., Ho D. H., LeBlanc B. In vitro studies of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 Feb;27(2):265–269. doi: 10.1128/aac.27.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Piccart M., Klastersky J., Meunier F., Lagast H., Van Laethem Y., Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870–875. doi: 10.1128/aac.26.6.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preheim L. C., Penn R. G., Sanders C. C., Goering R. V., Giger D. K. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 1982 Dec;22(6):1037–1041. doi: 10.1128/aac.22.6.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]